MK-7622

MK‑7622 is a small molecule investigational drug developed by Merck for the treatment of Alzheimer's disease. It is a highly selective positive allosteric modulator (PAM) of the M1 muscarinic acetylcholine receptor (M1R), designed to enhance cholinergic signaling in the brain without direct agonist activity. The compound belongs to the quinazolinone class and was intended as an adjunctive cognitive enhancer for patients with mild-to-moderate Alzheimer's disease already receiving acetylcholinesterase inhibitors. Clinical development was discontinued after Phase II trials showed no significant improvement in cognition or function compared to placebo, and higher rates of cholinergic adverse events were observed[1][4][8][9].

Other names

1227923-29-6DB12897DB-12897DB 12897D02WFND-02WFND 02WFNSCHEMBL2399084SCHEMBL-2399084SCHEMBL 2399084EX-A804EX-A-804EX-A 804JUVQLZBJFOGEEO-GOTSBHOMSA-NBCP27739BCP-27739BCP 27739ZINC95930184ZINC-95930184ZINC 95930184AKOS028113668AKOS-028113668AKOS 028113668CS-5442CS5442CS 5442HY-15618HY15618HY 15618Benzo(H)quinazolin‑4(3H)-one, 3‑((1S,2S)-2-hydroxycyclohexyl)-6‑((6-methyl‑3-pyridinyl)methyl)-